Homology Medicines Inc
NASDAQ:FIXX
Homology Medicines Inc
NASDAQ:FIXX
Price:
0.9347 USD
1 714.95%
Market Closed
Updated:
May 7, 2024
Homology Medicines Inc
Cash from Financing Activities
|
Homology Medicines Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Homology Medicines Inc
NASDAQ:FIXX
|
Cash from Financing Activities
$184k
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-74%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Homology Medicines Inc's Cash from Financing Activities?
Cash from Financing Activities
184k
USD
184k
USD
Based on the financial report for Dec 31, 2023, Homology Medicines Inc's Cash from Financing Activities amounts to 184k USD.
What is Homology Medicines Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-74%
-74%
Over the last year, the Cash from Financing Activities growth was -69%. The average annual Cash from Financing Activities growth rates for Homology Medicines Inc have been -85% over the past three years , -74% over the past five years .
You don't have any saved screeners yet
